Boston, United States
Quris AI, founded in 2019, is at the forefront of the AI-Pharma Revolution with its cutting-edge artificial intelligence technologies aimed at reshaping drug development. The company, headquartered in the United States, is making waves in the AI, Biotechnology, Health Care, Pharmaceutical, and Robotics industries.
At the heart of Quris AI's innovation is a machine-learning bio-platform designed to enhance the accuracy of predicting drug candidates that will safely function in humans, thereby circumventing the monumental expenses tied to failed clinical trials. This platform's promise is upheld by a robust team of top-tier scientists supported by strategic investors, allowing the company to position its first AI-based drug for upcoming clinical testing.
The company secured a $9.00M Seed Round investment on 20 December 2022, backed by prominent players such as iAngels, SoftBank Vision Fund, Welltech Ventures, Richter Group, and GlenRock Israel. This investment underlines the confidence investors have in Quris AI's transformative potential in the pharmaceutical domain.
